angioplasty

Disección coronaria en mujeres: poco frecuente y de difícil manejo

Revascularization in Spontaneous Coronary Artery Dissection Causing ST-Segment Elevation Myocardial Infarction

Spontaneous coronary artery dissection is an increasing cause of acute myocardial infarction, particularly in younger women. These infarctions are frequently treated conservatively given the risks entailed by revascularization, due to the possibility of causing an antegrade or retrograde expansion of the dissection. The uncertainty around treatment for these patients gave way to this study (recently<a href="https://solaci.org/en/2019/09/24/revascularization-in-spontaneous-coronary-artery-dissection-causing-st-segment-elevation-myocardial-infarction/" title="Read more" >...</a>

Los balones farmacológicos pasaron la prueba del tiempo en territorio femoropoplíteo

Drug Coated Balloons vs. Drug Eluting Stents in Primary PCI

There might come the time when we are finally able to leave nothing behind, at least in the context of primary PCI. The REVELATION study, soon to be published in J Am Coll Cardiol Intv, has shown that paclitaxel coated balloons resulted non inferior to drug eluting stents (DES) in terms of FFR (fractional flow<a href="https://solaci.org/en/2019/09/19/drug-coated-balloons-vs-drug-eluting-stents-in-primary-pci/" title="Read more" >...</a>

Dr. Gustavo Vignolo: “Jornadas le da a SOLACI una base de sustentación muy importante”

Dr. Gustavo Vignolo: “The Sessions Are a Significant Support Base for SOLACI”

Given the upcoming Panama and Ecuador 2019 Sessions, solaci.org interviewed Dr. Gustavo Vignolo (Sessions Assistant Director) and asked him about his vision for Latin American interventional cardiology and the importance of a project such as the Sessions to help this specialty reach all corners of our continent. — How is, in your experience, the current<a href="https://solaci.org/en/2019/09/18/dr-gustavo-vignolo-the-sessions-are-a-significant-support-base-for-solaci/" title="Read more" >...</a>

El FFR ahorra síntomas a los pacientes y costos a los financiadores de salud

Is Complete Revascularization the Right Choice in Acute Myocardial Infarction with Multivessel Disease?

Courtesy of Dr. Carlos Fava. Primary coronary angioplasty has been the treatment of choice for acute myocardial infarction (MI) for many years, but such strategy is associated with nonculprit lesions in a large group of patients. While it has been proven that nonculprit-lesion revascularization offers better outcomes, the groups that would benefit from it are<a href="https://solaci.org/en/2019/09/13/is-complete-revascularization-the-right-choice-in-acute-myocardial-infarction-with-multivessel-disease/" title="Read more" >...</a>

synergy vs XIENCE

Theoretical Advantages Translated into Worst Clinical Outcomes: Synergy vs. Xience

New data from a real-world registry soon to be published in J Am Coll Cardiol Intv suggest that Synergy (a thin-strut everolimus-eluting stent with a biodegradable polymer) is associated with a higher risk of acute stent thrombosis when compared with classic Xience (a thicker-strut everolimus-eluting stent with a durable polymer). At 12 months, there was<a href="https://solaci.org/en/2019/09/10/theoretical-advantages-translated-into-worst-clinical-outcomes-synergy-vs-xience/" title="Read more" >...</a>

ESC 2019 | EVOPACS: Evolocumab para reducir el colesterol en síndromes coronarios agudos

ESC 2019 | EVOPACS: Evolocumab to Reduce Cholesterol in Acute Coronary Syndromes

Eight weeks of treatment with evolocumab added to a regimen of high-intensity statins in patients with acute coronary syndrome reduced significantly LDL cholesterol levels and was safe, compared with statins + placebo, according to the EVOPACS study presented last Saturday at the European Society of Cardiology (ESC) Congress 2019 Scientific Sessions in Paris and simultaneously<a href="https://solaci.org/en/2019/09/06/esc-2019-evopacs-evolocumab-to-reduce-cholesterol-in-acute-coronary-syndromes/" title="Read more" >...</a>

ESC 2019 | DAPA-HF: Dapagliflozina muestra beneficios en todos los subgrupos

ESC 2019 | DAPA-HF: Dapagliflozin Shows Benefit for All Subgroups

Dapagliflozin (a sodium glucose co-transporter 2 [SGLT2] inhibitor), when indicated concomitantly with standard therapy, reduces significantly the risk of worsening heart failure events and cardiovascular events, and improves symptoms in patients with heart failure and reduced ejection fraction according to this new work presented during last Sunday’s scientific sessions at the European Society of Cardiology<a href="https://solaci.org/en/2019/09/06/esc-2019-dapa-hf-dapagliflozin-shows-benefit-for-all-subgroups/" title="Read more" >...</a>

ESC 2019 | New European Guidelines on “Chronic Coronary Syndromes”

In Paris, during the European Society of Cardiology (ESC) Congress 2019 Scientific Sessions, new guidelines for the diagnosis and treatment of chronic coronary syndromes were presented. This document, simultaneously published in Euro Heart J, updates the 2013 guidelines on stable ischemic heart disease and takes out the word “stable” so as to emphasize that the<a href="https://solaci.org/en/2019/09/05/esc-2019-new-european-guidelines-on-chronic-coronary-syndromes/" title="Read more" >...</a>

ESC 2019 | Complete: La evidencia definitiva para infartos con múltiples vasos

ESC 2019 | COMPLETE: Definitive Evidence for Infarction with Multivessel Disease

For patients with ST-segment elevation acute myocardial infarction and multivessel disease beyond the culprit artery, complete revascularization is superior to culprit-only treatment as regards the final endpoint, a composite of cardiovascular death, infarction, and ischemia-driven revascularization over a mean follow-up of 3 years. This information derives from long-awaited randomized study COMPLETE, finally presented at the<a href="https://solaci.org/en/2019/09/05/esc-2019-complete-definitive-evidence-for-infarction-with-multivessel-disease/" title="Read more" >...</a>

ESC 2019 | ISAR-REACT 5 | Prasugrel o ticagrelor en el SAC, ¿Cuál es mejor?

ESC 2019 | ISAR-REACT 5 | Which Is Better in ACS, Prasugrel or Ticagrelor?

Courtesy of Dr. Carlos Fava. The benefit of dual antiplatelet therapy in acute coronary syndromes (ACS) has been proven long ago, and both prasugrel and ticagrelor have offered best results than clopidogrel. However, nowadays, it is unclear which of them is superior in the long term, taking into account the fact that one starts to<a href="https://solaci.org/en/2019/09/05/esc-2019-isar-react-5-which-is-better-in-acs-prasugrel-or-ticagrelor/" title="Read more" >...</a>

Top